Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features * Presence of metastatic disease that can be biopsied by any methodology applicable * Ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue or orchiectomy (i.e., surgical or medical castration) * Serum testosterone level =\< 50 ng/dL at the screening visit * Progressive disease defined as one or more of the following three criteria (NOTE: Patients who received an antiandrogen must demonstrate disease progression following discontinuation of antiandrogen): * PSA progression defined by a minimum of two rising PSA levels with an interval of \>= 1 weeks between each determination. The PSA value at the screening visit should be \>= 2 ng/mL * Soft tissue disease progression as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) * Bone disease progression defined by two or more new lesions on bone scan * Patients previously treated with chemotherapy must have no more than two prior chemotherapy regimens for the treatment of metastatic prostate cancer * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Serum albumin \>= 3.0 g/dL * Serum potassium \>= 3.5 mmol/L * Estimated life expectancy of \>= 6 months * Able to swallow the study drug and comply with study requirements * Willing and able to give informed consent * Tumor specimen obtained prior to …